Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation (LOGICAL)
|ClinicalTrials.gov Identifier: NCT02074826|
Recruitment Status : Unknown
Verified February 2015 by Mathias Forkmann, Technische Universität Dresden.
Recruitment status was: Recruiting
First Posted : February 28, 2014
Last Update Posted : February 13, 2015
This prospective, single-centre cohort study aims to investigate the association between known genetic Atrial Fibrillation (AF) risk variants and the amount of left atrial fibrosis found in patients undergoing clinically indicated AF catheter ablation procedures.
Left atrial fibrosis is increasingly recognized as a fundamental part of the pathomorphological substrate creating an electrophysiological environment needed for electrical conduction heterogeneities. Such identification and treatment of left atrial fibrosis has already entered routine clinical use for RF catheter ablation in an attempt to develop an individualized and tailored treatment strategy. Today, it is unclear what impacts the development, the extent and the localization of left atrial fibrosis in different patients.
A number of genetic risk variants have been described that confer risk of AF and have been widely replicated. This indicates that genetic variants contribute to the risk of the individual to develop AF throughout his life. However, the mechanisms of how genetic variant impact the development of clinical arrhythmias is not yet well understood.
We hypothesize that genetic influences that lead to tissue changes may play a role in the development of the arrhythmia substrate for AF. This is likely to be especially true for those with a relatively brief history of AF and modest clinical disease burden. Therefore, we plan to investigate the association between known genetic AF variants and a detailed disease phenotype obtained from individual left atrial voltage mapping.
|Condition or disease|
Hide Detailed Description
The patient is referred for a radiofrequency (RF) ablation procedure for AF on clinical indications. All patients undergoing this procedure and fulfilling the inclusion criteria and not having any exclusion criteria are invited to participate in the study. After written informed consent, a patient is subjected to the study protocol of AF ablation. Detailed clinical information is obtained in addition to all data from imaging studies.
For genetic testing blood samples in EDTA (ethylenediaminetetraacetic) vacutainers will be collected from the study participants that will be performed at deCODE genetics in Reykjavik, Iceland. Samples will be frozen at -20°C and shipped to deCODE (deCODE genetics, Sturlugata 8, IS-101 Reykjavik, Iceland) in batches on ice. All sample handling, DNA isolation, and genotyping at deCODE will be performed in Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) accredited laboratories. The blood samples collected will be labelled using stickers with encrypted identifiers provided by deCODE. The key linking encrypted identifiers and the patient names will be stored in a secure location by the primary investigator in Dresden, Germany. The clinical data sent to deCODE will be encrypted in the same manner. Neither participants or third parties (e.g. health care insurance companies) will have any access to the genetic information collected.
Genotyping of the AF associated variants: DNA will be isolated in deCODE's CLIA and CAP accredited diagnostics laboratory from blood samples using the Chemagen method (Perkin Elmer). The SNPs (single nucleotide polymorphism) outlined in Table 1 will be genotyped using the Centaurus (Epoch Biosciences) platform. The genotyping of these markers have been analytically validated at deCODE using a comprehensive validated LIMS (Laboratory Information Management System) system that tracks every step in the process from registration to the final test report. Genotyping results for study participants will be stored in deCODE database under encrypted identifiers.
Prior to the ablation procedure, transesophageal echocardiography will be performed to exclude thrombus formation within the LA (left atrium). Electrophysiological studies are going to be performed in the post-absorptive state under deep sedation using midazolam and propofol. All antiarrhythmic medications will be discontinued at least five half-lives before the study, except amiodarone. Conventional 12-lead surface ECG (filtered 0.05-100 Hz) and bipolar intracardiac electrogram recordings (filtered 30-500 Hz) are amplified and displayed on Bard Laboratory System, (Bard Electrophysiology, Billerica, MA). A quadripolar and a decapolar catheter are introduced via the left femoral vein into the right ventricular apex and coronary sinus (CS) with a proximal pole at the CS ostium respectively. If atrial fibrillation (AF) is present in the beginning, a electric cardioversion (up to 3 times) will be performed to obtain sinus rhythm (SR).
A single transseptal puncture under fluoroscopic guidance will provide access into the LA. Repeated doses of heparin will be used to maintain an activated clotting time of 250 to 350 seconds throughout the whole procedure.
Mapping and ablation procedures will be guided by a 3D electroanatomical mapping system (CARTO 3, Biosense Webster, Inc., Diamond Bar, CA, USA or Ensite-Velocity, Endocardial Solutions, Inc., St. Paul, Minnesota, USA) in all patients. To quantify the amount of left atrial fibrosis, a bipolar voltage map will be carried out simultaneously during the CT-based 3D reconstruction of left atrium. All points will be taken in sinus rhythm. Radiofrequency alternating current will be delivered in a unipolar mode between the irrigated-tip electrode of the ablation catheter (Surround Flow, Biosense Webster or IBI Therapy CoolFlex, St. Jude Medical) and an external back plate electrode. The standard ablation settings include a preselected power of 40 W, and a flow rate of 15 or 17 ml/min (15 ml/min for Surround Flow, and 17 ml/min for CoolFlex). A temperature probe in the esophagus at the level of the LA is used to tag the esophageal location and to provide intraesophageal temperature feedback during the procedure. For the ablation procedure a ablation protocol is completed.
The following procedure data is recorded:
- Procedure date
- Initial rhythm: sinus rhythm, atrial fibrillation, atrial tachycardia
- Procedure time
- Fluoroscopy time and dose
- Ablation duration
- Ablation energy
- Isolation of each pulmonary vein
- Adverse events / procedure-related events: tamponade, stroke, myocardial infarction, pulmonary embolism, pulmonary edema
The primary end point is reached when a detailed endocardial voltage mapping has been performed and correlated with the suggested genetic AF markers.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1000 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Analysis of the Interplay Between Genetic Risk Variants for Atrial Fibrillation and Pathological Changes That Associate With the Disease|
|Study Start Date :||March 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
- Association between the suggested genetic AF risk variants and the amount of left atrial low voltage zones [ Time Frame: baseline ]The primary endpoint of the study measures the association between the suggested genetic AF risk variants and the amount of left atrial fibrosis found on detailed endocardial voltage mapping.
- Fluoroscopy exposure [ Time Frame: baseline ]
- Procedural ablation duration [ Time Frame: baseline ]
- Freedom from recurrences of AF or MRT (magnetic resonance tomography) after substrate guided AF ablation during follow up [ Time Frame: 6 and 12 months after inclusion ]
- Association between the proposed genetic markers and the patients clinical characteristics [ Time Frame: baseline ]
- Association between the proposed genetic markers and short and long term ablation success [ Time Frame: 6 and 12 months afte inclusion ]
- Association between the proposed genetic markers and hard clinical outcome parameters [ Time Frame: 6 and 12 months after inclusion ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074826
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074826
|Contact: Mathias Forkmann, Dr. med.||+ 49 351 450 firstname.lastname@example.org|
|Contact: Yan Huo, Dr. med.||+ 49 351 450 email@example.com|
|Heart Center Dresden, Depart. of Electrophysiology||Recruiting|
|Dresden, Germany, 01307|
|Contact: Mathias Forkmann, Dr. med. + 49 351 450 1901 firstname.lastname@example.org|
|Contact: Yan Huo, Dr. med. + 49 351 450 1901 email@example.com|
|Principal Investigator: Christopher Piorkowski, PD|
|Study Chair:||Christopher Piorkowski, PD||Department of Electrophysiology, University of Dresden - Heart Center|
|Study Chair:||David O. Arnar, Dr||Department of Cardiology, Landspitali University Hospital Heart|
|Principal Investigator:||Thomas P Gaspar, Dr.||Department of Electrophysiology, University of Dresden - Heart Center|
|Principal Investigator:||Mathias Forkmann, Dr.||Department of Electrophysiology, University of Dresden - Heart Center|